LLY

949.03

+1.48%↑

NVO

142.18

+1.62%↑

UNH

511.99

+1.33%↑

JNJ

149.82

+0.04%↑

MRK

127.38

-1.16%↓

LLY

949.03

+1.48%↑

NVO

142.18

+1.62%↑

UNH

511.99

+1.33%↑

JNJ

149.82

+0.04%↑

MRK

127.38

-1.16%↓

LLY

949.03

+1.48%↑

NVO

142.18

+1.62%↑

UNH

511.99

+1.33%↑

JNJ

149.82

+0.04%↑

MRK

127.38

-1.16%↓

LLY

949.03

+1.48%↑

NVO

142.18

+1.62%↑

UNH

511.99

+1.33%↑

JNJ

149.82

+0.04%↑

MRK

127.38

-1.16%↓

LLY

949.03

+1.48%↑

NVO

142.18

+1.62%↑

UNH

511.99

+1.33%↑

JNJ

149.82

+0.04%↑

MRK

127.38

-1.16%↓

Search

Ardelyx Inc

Suletud

Sektor Tervishoid

5.89 0.68

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.8

Max

5.89

Põhinäitajad

By Trading Economics

Sissetulek

-33M

-27M

Müük

12M

46M

Aktsiakasum

-0.11

Kasumimarginaal

-57.619

Töötajad

267

EBITDA

-30M

-22M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+85.57 upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

31. juuli 2024

Turustatistika

By TradingEconomics

Turukapital

-116M

1.4B

Eelmine avamishind

5.21

Eelmine sulgemishind

5.89

Uudiste sentiment

By Acuity

13%

87%

12 / 369 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

Ardelyx Inc Graafik

Seotud uudised

18. okt 2023, 12:15 UTC

Suurimad hinnamuutused turgudel

Ardelyx Shares Rally Premarket on FDA Approval of Xphozah

Võrdlus sarnastega

Hinnamuutus

Ardelyx Inc Prognoos

Hinnasiht

By TipRanks

85.57% tõus

12 kuu keskmine prognoos

Keskmine 10.93 USD  85.57%

Kõrge 15 USD

Madal 7 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Ardelyx Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

6

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

5.56 / 5.97Toetus ja vastupanu

Lühikene perspektiiv

Neutral Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

12 / 369 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ardelyx Inc

Ardelyx, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines to improve treatment for people with kidney and cardiorenal diseases. The Company's product pipeline includes Tenapanor, IBSRELA, RDX013 Program, and RDX020 Program. The Tenapanor is a medicine for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor for the control of serum phosphorus has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). RDX013 Program is a small molecule potassium secretagogue program for the potential treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis. It has a discovery program targeting the inhibition of intestinal bicarbonate exchange for the treatment of metabolic acidosis.